Congenica Inherited Cancer
Inherited Cancers
While most cancers develop spontaneously, around 5% of cancer diagnoses are linked to certain genetic markers that are passed down generations. Harbouring any of these variations doesn't automatically mean that an individual develops cancer, however, it certainly puts this person at greater risk.
Cancer types typically associated with inherited variants
Breast Cancer (BRCA1, BRCA2, PALB2)
Ovarian Cancer (BRCA1, BRCA2)
Pancreatic Cancer (BRCA1, BRCA2)
Prostate Cancer (BRCA1, BRCA2)
Li-Fraumeni Syndrome (TP53)
Hereditary non polyposis colon cancer/Lynch Syndrome (MLH1, MSH2, MSH6, PMS2)
Hamartoma Tumour Syndrome (PTEN)
Familial adenomatous polyposis (APC)
MUTYH associated polyposis (MUTYH)
Peutz Jeghers Syndrome (STK11)
Juvenile Polyposis Syndrome (SMAD4, BMPR1A)
Von Hippel Lindau Syndrome (VHL)
Tuberous sclerosis (TSC1, TSC2)
Birt-Hogg-Dube Syndrome (FLCN)
Multiple endocrine neoplasia type 1 and 2 (RET)
Retinoblastoma (RB1)
Familial Atypical Multiple Mole Melanoma Syndrome (CDKN2A)
Hereditary papillary cancer (MET, FH)
Identifying causative variants helps patient management, ensures potential tumours are detected as early as possible, provides options for preventative treatments and helps understand the implications for family members.
With our scalable, automated and cost-effective analysis platform, Congenica gives you the actionable insights that you need to deliver life-changing answers to patients and their families.
Rapid turnaround time
Automated processes for fast and accurate analysis supported by machine learning and AI
Increased interpretation yield
Increased interpretation yield through automated variant prioritisation and expertly curated reference databases
Commitment to quality
Validated, accurate and secure platform for high confidence in actionable clinical information (see footnote for further details)
Ultimate flexibility
From gene panels to whole genomes, SaaS or on premise, we offer ultimate flexibility to support all customer needs